Irras is a commercial-stage medical technology company formed to develop and commercialize devices for a broad range of brain pathology therapeutic applications and procedures. It is led by Executive Chairman and acting CEO Kleanthis G. Xanthopoulos, Ph.D. Its flagship product, IRRAflow™, is a medical device that provides intelligent, dynamic control of central nervous system fluids to address complications associated with hemorrhagic stroke. The company has operations in Germany and La Jolla, USA. Irras will use the new funding to support EU commercial growth and to pursue regulatory approval in the US. The company is based in Stockholm, Sweden.

Total raised

$11M

Funding rounds

1

Latest round

Equity

Latest activity

May 2016